[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics.Pharmaceuticals Division sales were +7% at CER, -4% when reported in CHF and +10% in USD, due to continued high growth in sales of medicines for the treatment of severe diseases; Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases) and Ocrevus (multiple ...